National Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design Considerations

Overview of attention for article published in Journal of Clinical Oncology, October 2025

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (95th percentile)
Good Attention Score compared to outputs of the same age and source (70th percentile)

Mentioned by

twitter: 37 X users
guideline: 1 clinical guideline source

bluesky: 2 Bluesky users
podcasts: 1 podcast

Readers on

mendeley: 4 Mendeley

So far, Altmetric has seen 2 Bluesky posts from 2 Bluesky users, with an upper bound of 574 followers.

Lots of ❓s in defining benefits of “#oligomet” or “#MDT” therapy in #ProstateCancer ❓ADT+/-ARPI? How long? ❓PFS vs Eugonadal PFS? ❓how many mets? Where? 🔑❓what imaging 🩻❓ #PSMA mets🚫🟰CT/Bone scan mets shorturl.at/n3JwU Std of Care? Or just so…

For more: bit.ly/4octcCV

This page shows the most recent Bluesky posts that mention this research output. Click here to find out how to access more activity.